Jose Luis Lopez-Campos
Overview
Explore the profile of Jose Luis Lopez-Campos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
252
Citations
2754
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Calle Rubio M, Cataluna J, Miravitlles M, Navarrete B, Lopez-Campos J, Ferrer M, et al.
J Clin Med
. 2025 Feb;
14(3).
PMID: 39941377
: the concept of clinical control of COPD is a measure proposed in the Spanish COPD Guidelines (GesEPOC), which aims to help clinicians assess the clinical status in order to...
2.
Calle Rubio M, Miravitlles M, Cataluna J, Lopez-Campos J, Navarrete B, Ferrer M, et al.
PLoS One
. 2025 Jan;
20(1):e0314299.
PMID: 39787174
Objective: This study aimed to evaluate clinical control in chronic obstructive pulmonary disease (COPD), the consequences in terms of treatment decisions, and their potentially associated factors during follow-up of patients...
3.
Figueira-Goncalves J, Lopez-Campos J
Arch Bronconeumol
. 2024 Dec;
61(3):127-128.
PMID: 39676021
No abstract available.
4.
Lopez-Campos J, Manresa Presas F, Ruiz Manzano J, Perpina Tordera M, Casan Clara P, Garcia-Rio F, et al.
Arch Bronconeumol
. 2024 Oct;
PMID: 39426893
No abstract available.
5.
Arija R, de la Espada R, Ollero M, Hernandez L, Gallego E, Lopez-Campos J
Ann Fam Med
. 2024 Sep;
22(5):417-420.
PMID: 39313335
The aim of this work is to test whether the use of a transparent capsule affects the residual capsule weight after inhalation as a surrogate of the inhaled delivered dose...
6.
Enriquez-Rodriguez C, Casadevall C, Faner R, Pascual-Guardia S, Castro-Acosta A, Lopez-Campos J, et al.
Cells
. 2024 Aug;
13(16).
PMID: 39195241
Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of global mortality. Despite clinical predictors (age, severity, comorbidities, etc.) being established, proteomics offers comprehensive biological profiling to obtain deeper...
7.
Ersoz H, Torres-Duran M, Turner A, Tanash H, Rodriguez Garcia C, Corsico A, et al.
Arch Bronconeumol
. 2024 Jul;
61(1):22-30.
PMID: 39068055
Background: Sex and gender influence many aspects of chronic obstructive pulmonary disease (COPD). Limited data are available on this topic in alpha-1 antitrypsin deficiency (AATD). We therefore aimed to investigate...
8.
Martin T, Guimaraes C, Esquinas C, Torres-Duran M, Turner A, Tanash H, et al.
Respir Res
. 2024 Jun;
25(1):260.
PMID: 38926693
Background: The PI*S variant is one of the most prevalent mutations within alpha-1 antitrypsin deficiency (AATD). The risk of developing AATD-related lung disease in individuals with the PI*SS genotype is...
9.
Cayuela L, Gaeta A, Lopez-Campos J, Cayuela A
Clin Transl Oncol
. 2024 Jun;
27(1):189-195.
PMID: 38896340
Background: This study examines lung cancer incidence in Spain (1990-2019) through age-period-cohort (A-P-C) analysis and Global Burden of Diseases (GBD) data, unravelling the complex interplay of age, period, and birth...
10.
Agusti A, Lopez-Campos J, Miravitlles M, Soler-Cataluna J, Marin J, Cosio B, et al.
Arch Bronconeumol
. 2024 May;
60(7):417-422.
PMID: 38729884
Introduction: Treatment with LABA/LAMA is recommended in GOLD B patients. We hypothesized that triple therapy (LABA/LAMA/ICS) will be superior to LABA/LAMA in achieving and maintaining clinical control (CC), a composite...